anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This randomized, interventional, cancer care delivery trial will test whether receipt of Geriatric Assessment (GA) and Objective Functional Status (OFS) assessment data affects older adults' treatment priorities. It will also assess the preferences of older adults for the collection, sharing, and use of their assessment data. Finally, it will explore whether less fit patients experience a lower level of satisfaction and a greater degree of regret with their decision to undergo anti-cancer therapy. This study will utilize a randomized design where participants will be randomized to either the intervention arm (early sharing of GA and OFS results) or to the control arm (delayed sharing of GA and OFS results). To assess patients' preferences for quality vs quantity of life, the investigators will use the Quality Quantity (QQ) questionnaire. All patients will complete this at baseline and then undergo their GA and OFS assessments. Patients randomized to the intervention group will be provided the results of their GA and OFS assessments, and then complete the QQ Questionnaire for a second time to assess for any changes following receipt of their assessment results. Patients randomized to the control group will undergo the assessments and complete the same questionnaire as the intervention group but will not receive the results of their GA and OFS assessments prior to completing the second QQ Questionnaire. For the control group, assessment results will be shared with patients after completion of the follow-up QQ Questionnaire. After reviewing their assessment results, patients in both groups will then complete a questionnaire that inquire about their preferences for receipt, use, and sharing of their assessment data. It will also inquire about the degree to which receipt of these data affected how they experienced their cancer care.

The Investigators will determine whether sharing of geriatric and OFS assessment results affected patients' treatment priorities by measuring the absolute change from baseline in the QQ questionnaire scores for quantity and quality of life, comparing the change in the intervention versus the control group. The Investigators will also describe patients' preferences for the collection, use and sharing of their assessment data as reported in the preferences questionnaire, both overall and by race/ethnicity. To explore differences in patients' satisfaction with their decision to pursue anti-cancer therapy by functional status level, participants will complete the "Was it Worth It" (WIWI) questionnaire at the first of either 1) the conclusion of their treatment regimen or 2) three months after enrollment. The provider assessment will ask whether patients experienced any of the following: a toxicity of treatment ≥grade 3, treatment dose reduction, treatment interruption, treatment discontinuation, hospitalization, or a decline in performance status.
FIELD: cosmetology. SUBSTANCE: the present innovation deals with components increasing aroma of cosmetic compositions and capable to highly remove unpleasant odor of human body. Thus, it is provided the decrease of total amount of aromatizing constituent necessary to obtain satisfactory cosmetic preparation, against perspiration, in particular. Aroma-increasing compositions are obtained due to combining, at least, three components chosen out of the group consisting of nonnitromusk substances. EFFECT: higher efficiency. 16 cl, 5 tbl
This arm of the study will receive cognitive behavioral therapy with exposure in vivo. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
Patients undergo nTMS over 1 hour. Patients also perform 4 tasks that test grip and pinch strength, and the ability to use and feel with their hands for 1 hour.
CPAP is the treatment of choice for patients with OSA. However, patients are frequently intolerant of this therapy initially. After continued use, tolerance is achieved. However, this initial discomfort or intolerance frequently leads to a patient-initiated discontinuation of therapy. It has been shown that CPAP use at 1 month predicts use at 6 months and 1 year. Patients who initially struggle with or are intolerant of CPAP frequently abandon therapy and are unlikely to use it long term. To prevent this, sleep physicians often prescribe short courses of sedatives to help improve initial tolerance and promote better compliance with therapy. However, the effectiveness of this practice has not been validated in a clinical trial. Compliance, in reference to this study is the willingness of the patients to follow the prescribed course of treatment.
PURPOSE: The aim of study was to employ the Cycle Generative Adversarial Network (CycleGAN) deep learning model to diminish the cerebrospinal fluid (CSF) flow artifacts in cervical spine MRI. We also evaluate the agreement in quantifying spinal canal stenosis.
METHODS: For training model, we collected 9633 axial MR image pairs from 399 subjects. Then, additional 104 image pairs from 19 subjects were gathered for the test set. The deep learning model was developed using CycleGAN to reduce CSF flow artifacts, where T2 TSE images served as input, and T2 FFE images, known for fewer CSF flow artifacts. Post training, CycleGAN-generated images were subjected to both quantitative and qualitative evaluations for CSF artifacts. For assessing the agreement of spinal canal stenosis, four raters utilized an additional 104 pairs of original and CycleGAN-generated images, with inter-rater agreement evaluated using a weighted kappa value.
RESULTS: CSF flow artifacts were reduced in the CycleGAN-generated images compared to the T2 TSE and FFE images in both quantitative and qualitative analysis. All raters concordantly displayed satisfactory estimation results when assessing spinal canal stenosis using the CycleGAN-generated images with T2 TSE images (kappa = 0.61-0.75) compared to the original FFE with T2 TSE images (kappa = 0.48-0.71).
CONCLUSIONS: CycleGAN demonstrated the capability to produce images with diminished CSF flow artifacts. When paired with T2 TSE images, the CycleGAN-generated images allowed for more consistent assessment of spinal canal stenosis and exhibited agreement levels that were comparable to the combination of T2 TSE and FFE images.
American Society of Anaesthesiologist physical status II-III, aged between 2-12, 60 patients which underwent open cardiac surgery will recruited to this study. The patients were randomly allocated into two groups (1:1), via a computer-generated randomization list. Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the 30 patients under general anaesthesia in Group block and block will not perform to the control group. Sevoflurane+remifentanil and O2/air combination will perform to the all patients during the surgery. Totally bupivacaine %0.25 2.5 mg/kg will use for blocks.2 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery. 0.1 microgram/kg morphine intravenously will apply for postoperative analgesia to the all patients at last 30 minutes of surgery. Postoperative pain and agitation assessment will perform with FLACC and Watcha scores. FLACC, Watcha scores, morphine consumption and complications will record.Paracetamol 10 mg/kg will repeat to the all patients at the 12th of postoperative period, intravenously. The patient controlled anesthesia with morphin will apply to the all patients. If the FLACC score is higher than 4, morphine 0.015 mg/kg will administer intravenously.
Cardiac arrhythmias and sudden death are frequent in patients with non-ischemic cardiomyopathy and can precede heart failure or additional symptoms where malignant cardiac arrhythmias are mostly the consequence of advanced cardiomyopathy and heart failure. Finding these subgroups and making an early diagnosis could be lifesaving. In our retrospective study, we are presenting arrhythmic types of frequent cardiomyopathies where an arrhythmogenic substrate is less well defined, as in ischemic or structural heart disease. In the period of 2 years, next-generation sequencing (NGS) tests along with standard clinical tests were performed in 208 patients (67 women and 141 men; mean age, 51.2 ± 19.4 years) without ischemic or an overt structural heart disease after syncope or aborted sudden cardiac death. Genetic variants were detected in 34.4% of the study population, with a significant proportion of pathogenic variants (P) (14.4%) and variants of unknown significance (VUS) (20%). Regardless of genotype, all patients were stratified according to clinical guidelines for aggressive treatment of sudden cardiac death with an implantable cardioverter defibrillator (ICD). The P variant identified by NGS serves for an accurate diagnosis and, thus, better prevention and specific treatment of patients and their relatives. Results in our study suggest that targeted sequencing of genes associated with cardiovascular disease is an important addendum for final diagnosis, allowing the identification of a molecular genetic cause in a vast proportion of patients for a definitive diagnosis and a more specific way of treatment. VUS in this target population poses a high risk and should be considered possibly pathogenic in reanalysis.
Renal Toxicity  
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. 

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of NAPRELAN in patients with advanced renal disease. The renal effects of NAPRELAN may hasten the progression of renal dysfunction in patients with preexisting renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating NAPRELAN. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of NAPRELAN [see Drug Interactions (7)]. Avoid the use of NAPRELAN in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If NAPRELAN is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia   
Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
A retrospective cohort analysis was performed comparing patients that had intra operative antegrade liver reperfusions versus patients that had retrograde liver perfusion. Antegrade Reperfusion(ATR) group: after completing the caval replacement or piggy-back, for IVC anastomosis, Portal vein (PV) anastomosis was done with a running suture as normal fashion, then it was followed by the removal the clamps, starting by the supra hepatic VC, followed by the PV clamp and finally the infrahepatic VC. It was followed by arterial anastomosis and the biliary anastomosis (duct-to-duct if possible). Retrograde group (RETR): after completing the piggyback the IVC was declamped immediately and retrograde low pressure reperfusion of the graft with low oxygenated venous blood was established. Central venous pressure was intended to be higher than in 8 mmHg to enable appropriate retrograde reperfusion in the transplanted liver. Significant venous backflow via portal vein appears immediately after declamping. Venous bleeding from the liver except portal backflow was stopped immediately after declamping the venous anastomosis, as appropriate. Portal vein anastomosis was performed using running suture. It was followed by arterial anastomosis and the biliary anastomosis (duct-to-duct if possible). The endpoints are patient survival and graft survival at 1, 3,5, 10 years post liver transplantation in both groups. To adjust for a selection bias, we will perform a propensity score analysis.
The Validol medicamentous form is a 25-30% menthol solution in menthyl ester of isovalerianic acid and auxiliary substances. The active composition is directly adsorbed on carriers of colloid silicon dioxide and sorbitol after which it is directly made into tablets. By the method the medicamentous form is produced without granulation and drying. The finished tablets have no mosaic structure of incompletely adsorbed oily substance. The medicamentous form has improved stability as a result of the complete adsorption of the Validol. The application of the preparation is extended by means of substitution of the saccharose with Sorbitol.
Electrical impedance tomography will be used to verify the effect of the lateral posture and associated breathing techniques in COPD and healthy individuals. The subjects will be placed in a standardised position before the measurements begin. The subjects will be placed in a right lateral recumbency position. The protocol comprises four manoeuvres, each interrupted by a short rest phase. Each subject will begin the experiment with the spontaneous ventilation manoeuvre in order to obtain the reference ventilation distribution. This will be followed by four other manoeuvres during which ventilation was measured: 1) using an spirometer to obtain a tidal volume of 1L, 2) performing the ELTGOL technique independently, 3) performing the ELTGOL technique assisted by manual pressures applied by a physiotherapist. 4) using a positive expiratory pressure (PEP) device.
Dementia is a significant public health crisis; the most common underlying cause of age-related cognitive decline and dementia is Alzheimer's disease neuropathologic change (ADNC). As such, there is an urgent need to identify novel therapeutic targets for the treatment and prevention of the underlying pathologic processes that contribute to the development of AD dementia. Although age is the top risk factor for dementia in general and AD specifically, these are not inevitable consequences of advanced age. Some individuals are able to live to advanced age without accumulating significant pathology (resistance to ADNC), whereas others are able to maintain cognitive function despite the presence of significant pathology (resilience to ADNC). Understanding mechanisms of resistance and resilience will inform therapeutic strategies to promote these processes to prevent or delay AD dementia. This article will highlight what is currently known about resistance and resilience to AD, including our current understanding of possible underlying mechanisms that may lead to candidate preventive and treatment interventions for this devastating neurodegenerative disease.
PURPOSE:To provide the titled cosmetic containing powder and an oil phase having a specific viscosity, separable into an upper oil phase and a lower pow der phase out of use when placed on a table, forming a uniformly dispersed liquid by shaking and mixing the components in use and giving beautiful make-up effect. CONSTITUTION:A two-layered liquid make-up cosmetic containing an oil phase (e.g. liquid paraffin, minke oil, oleic acid, etc.) having a viscosity of <=500cps. at 25 deg.C and powder (e.g. talc, kaolin, silica, alumina, titanium oxide, etc.) Addi tion of a volatile oil component having a boiling point of <=260 deg.C under atmo spheric pressure to the oil phase gives a cosmetic having smooth spreadability on the skin, giving no load to the skin, giving refreshing feeling after application and having improved water-resistance, oil-resistance and sebum-resistance. The water-resistance, oil-resistance and sweat-resistance can be further improved by the combined use of a silicone oil and a silicone resin as the oil component and the redispersibility of the powder can be improved compared with a cosmet ic containing other oil component.
Women were assigned randomly using a computer-generated random numbers table to either an Exercise and Nutrition Group (ENG) or a Control Group (CG). The women received step-by-step instructions on how to complete a consecutive 3-day food record (including two week-days and one weekend day) and an exercise log for 7 days using a pedometer (YAMAX SW-200 Digi-Walker) to determine steps/day. The information and instruction were delivered to the women in English or Arabic. Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively. Women came to the lab after a 12 hour fast and a blood sample was drawn. Waist and hip measurements were taken along with resting blood pressure. Estimated fitness levels was measured by a trained kinesiologist using a Step Test (Siconolfi et al. 1985). All baseline measurements, including the 3-day food intake record and the 7-day pedometer step count log were repeated at the end of the 12-week intervention in both groups. The ENG group attended a supervised women-only exercise program that presented Arabic music and traditional dance steps (the Lebanese Dabka) three times a week in the London Muslim Mosque Gym and received nutrition education over the 12 weeks, one session per week.
Behavioral and weight loss intervention, with regular sodium intake. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking.
The present invention relates to a composite and a method for reducing post-operative adhesion of tissues. The composite includes a biocompatible, biodegradable support, and a water-insoluble hyaluronic acid derivative at the support. The hyaluronic acid derivative includes an N-acylurea that results from cross-linking by the reaction of hyaluronic acid with a multifunctional carbodiimide. Optionally, a monocarbodiimide also may be employed. A  pharmaceutically-active molecule may be added to the N-acylurea derivative of hyaluronic acid. Although the composite includes material that prevents adhesion between tissues, in order to reduce the need for suturing when the composite is being used during a surgical procedure, a material that enhances adhesion of the composite to tissues may be applied to a surface of the composite. A method of forming the composite for reducing post-operative adhesion of tissues, including the step of applying an N-acylurea derivative of hyaluronic acid resulting from cross-linking with a multifunctional carbodiimide, to a biocompatible, biodegradable support; a method of preparing a drug delivery vehicle that includes a pharmaceutically-active molecule with the N-acylurea derivative of hyaluronic acid resulting from cross-linking with a multifunctional carbodiimide; and a method of reducing post-operative adhesion of tissues are disclosed.
Systems, methods, and apparati for screening libraries, particularly display libraries are disclosed. Methods can be automated or at least partially machine-based. Also disclosed are software and databases that interface with a library screening process such as a display library screening process. A computer system can be used to store, manage, and generate information that includes assay results and sample tracking from various automation stations. The system can include interfaces for project management, data analysis, and sample tacking and auditing. A database can manage hits identified during screening of a library. The database can be a relational database that includes tables for projects, libraries, screens, and hits.
BACKGROUND The brachial plexus is a complex neural structure providing motor and sensory innervation to structures of the arm, shoulder, and upper chest. The anatomical structure is typically divided into roots, trunks, divisions, and cords. Due to the presence of multiple nerve roots and branches, anatomical variations are common. Awareness of variations from normal anatomy is important in imaging, administration of nerve blocks, and surgical procedures of the neck and shoulder region. CASE REPORT We present a case of multiple anatomic variations of the right brachial plexus identified in a cadaver during routine dissection. To summarize, we identified a prefixed plexus with anomalous contributions from the C4 nerve root. Nerve roots C4 and C5 emerged anterior to the anterior scalene muscle. Furthermore, 4 trunks, rather than the typical 3, gave rise to multiple anomalies in the branching pattern of the distal divisions and cords. To the best of our knowledge, this is the first such case reported in the published literature. CONCLUSIONS The current case report presents a combination of brachial plexus anomalies not previously described in the medical literature - specifically, a prefixed (C4-T1) brachial plexus positioned anterior to the anterior scalene muscle with anomalies of the trunks, divisions, cords, and terminal branches. The variations presented have implications in neurogenic compression, interscalene blocks, and trauma to the upper limb. Knowledge of these anomalies may better equip anatomists and clinicians to understand pathology and intervention of the upper limb.
Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 4-5. This is the "moderate sedation" arm.
A solid dispersion or medicinal solid dispersion preparation which comprises a water-soluble polymer and either a phenylalanine compound represented by the formula (1) [wherein A represents the formula (2), etc.; B represents alkoxy, etc.; E represents hydrogen, etc.; D represents substituted phenyl, etc.; T, U, and V each represents carbonyl, etc.; Arm represents a benzene ring, etc.; R1 represents alkyl, etc.; R2, R3, and R4 are the same or different and each represents hydrogen, substituted amino, etc.; and J and J' each represents hydrogen, etc.] or a pharmaceutically acceptable salt of the compound; a process for producing the dispersion or preparation; and a solubilized medicinal preparation which comprises the compound (I) or pharmaceutically acceptable salt and a dissolution agent. Although the medicinal solid dispersion preparation or solubilized medicinal preparation contains as an active ingredient a phenylalanine compound represented by the formula (1), which is a sparingly soluble drug, it has high solubility and high oral absorbability.
A chemical contraception system is described in which the spermicidal chemical, for example, "Nonoxynol-9", is provided in a powder or tablet form and is dissolved in a solvent, primarily water, immediately before use. The solution containing the spermacide is then allowed to soak into an applicator matrix, such as a sponge or pad. The spermicide-impregnated matrix is inserted into the vagina and later removed. The system can be provided in kit form (FIGS. 1 and 2) including a storage container for the powder, a mixing container, and a measuring spoon, or in a pre-packaged form where the chemical has already been added to the sponge. Among the preferred embodiments of the system are the use of the spermicidal chemical in powder or tablet form and the use of a sponge for vaginal retention of the spermicidal solution.
Participants will receive 7.4 GBq (+/- 10%) of AAA617 (Lutetium \[177Lu\] vipivotide tetraxetan) once every 6 weeks for 6 cycles. In addition of SOC (ADT plus choice of ARPI as per physician's decision), Best supportive care is allowed.